Synthekine
Founded 2018 · 56 employees on LinkedIn · 9 known investors
Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy. Its pipeline targets cancer and inflammatory diseases.
Founders & leadership
Synthekine was founded in 2018 by K. Christopher Garcia.
Investors · 9
Samsara BioCapital✓ verifiedPalo Alto
The Column Group✓ verifiedSan Francisco · $30M
Bain Capital Life SciencesBoston
Canaan PartnersStamford · $500K – $20M
RA CapitalBoston
TCG CrossoverPalo Alto
Deerfield Management CompanyreportedNew York
Janus Henderson InvestorsreportedNew York
Rock Springs CapitalreportedBaltimore
Funding
SEC filings, press & company announcements$107M disclosed across 1 of 3 rounds · 2021–2023
- Undisclosed amountSeries CJan 2023
The Column Group (lead)
Source ↗ - $107MSeries BJun 2021 · 3 sourcesSource ↗
- Undisclosed amountB roundJun 2021Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Synthekine do?
- Synthekine is a clinical-stage biotechnology company using protein engineering platforms to develop cytokine-based immunotherapies designed to preserve therapeutic efficacy while avoiding toxicities linked to cytokine pleiotropy. Its pipeline targets cancer and inflammatory diseases.
- Who founded Synthekine?
- Synthekine was founded by K. Christopher Garcia in 2018.
- Who are Synthekine's investors?
- Synthekine's investors include Samsara BioCapital, The Column Group, Bain Capital Life Sciences, Canaan Partners, RA Capital, TCG Crossover, Deerfield Management Company, Janus Henderson Investors and 1 more.
- How much funding has Synthekine raised?
- Synthekine has disclosed $107M raised across 1 of its 3 known rounds.